Recipharm AB acquires Abbott Manufacturing Site in Spain

05-Oct-2010 - Spain

Recipharm AB announced that they have acquired Abbott’s (formerly Solvay Pharmaceuticals) manufacturing site in Parets, close to Barcelona, Spain for an undisclosed sum. Parets produces solid dose, sterile ointments, oral liquids, aerosols and topical products. The site, which has benefited from high levels of Investment in recent years, is well suited to the flexible requirements of a contract manufacturing operation, already servicing a number of companies. The newly acquired business will be called Recipharm Parets SL.

This move further enhances Recipharm’s capabilities, providing a base in the strategically important Spanish market, whilst bringing new customer relationships into the Recipharm Group. It also reinforces Recipharm’s strategic goal to become one of the world’s leading Contract Development and Manufacturing Organisations (CDMO), offering a ‘one-stop shop’ for the development and manufacturing of both small and large molecule biopharmaceuticals.

Recipharm will continue to produce all Abbott products currently manufactured at the site. Recipharm also intends to retain all existing employees.

Other news from the department manufacturing

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world biopharmaceutical manufacturing

Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.

20+ products
15+ brochures
View topic world

Topic world biopharmaceutical manufacturing

Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.

20+ products
15+ brochures